Sachin Phakey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sachin Phakey has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Lyndell Lp Lim
Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital Melbourne Victoria Australia
3 shared publications - Anthony J. Hall
Department of Ophthalmology Alfred Hospital Melbourne Victoria Australia
2 shared publications Angeline Shen
MBBS, FRACP, Consultant Endocrinologist, Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Vic; Consultant General Physician, Department of General Medicine, The Royal Melbourne Hospital, Melbourne, Vic
1 shared publication- Elaine W. Chong
The Royal Melbourne Hospital, Parkville, Victoria, Australia
1 shared publication Jasmine Lichtenstein
Centre for Eye Research Australia The Royal Victorian Eye and Ear Hospital East Melbourne Victoria Australia
1 shared publication- Katherine Beverley Gibney
Department of Infectious Diseases University of Melbourne at the Peter Doherty Institute for Infection and Immunity Melbourne Australia
1 shared publication
Latest Publications
- 13 December 2024
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 32 (5) , 533-542
Corneal Transplantation in Australia Over 29 Years: A Retrospective Analysis of Medicare Data from 1994 to 2022
We aim to report the frequency and distribution of corneal transplantation, by age, sex, and state/territory, in Australia over a > 25-year period from 1994 to 2022, including during COVID-19 lockdowns. Using data from Medicare, Australia's Government-funded health insurance scheme, we retrospectively analysed corneal transplants performed from January 1994 to December 2022. From 1994 to 2022, there were 27,536 corneal transplantation services processed by Medicare. Transplants tended to be more common in males in younger age groups (67.7% male in 15-24-year-olds), and in females in older age groups (59.2% female in 75-84-year-olds). Most transplants were performed in New South Wales (9,438 services, 34.3%), Queensland (7,722, 28.0%), and Victoria (5,209, 18.9%). Annual corneal transplantation rates in Australia tended to decrease from 1994 to 2006 (lowest rate during study period), falling by 31%, and then increased by 81%, from 2006 to 2022 (end of study period). Annual repeat corneal transplantation rates (i.e. second and subsequent transplants) increased from 2004 to 2022, rising 301%. During Australia's nationwide 2020 COVID-19 lockdown (from March to April), monthly transplantation rates decreased by 31%. We performed a longitudinal analysis of corneal transplantation in Australia using a comprehensive, routinely collected, population-based data source. Prior studies examining corneal transplantation have interrogated data from the Australian Corneal Graft Registry, which relies on voluntary reporting. Corneal transplantation rates have increased during the last 15 years, likely as new corneal transplant techniques have evolved, with increasing demand for corneal donation and eye banking services.
- 13 December 2024
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 32 (5) , 533-542
Corneal Transplantation in Australia Over 29 Years: A Retrospective Analysis of Medicare Data from 1994 to 2022
We aim to report the frequency and distribution of corneal transplantation, by age, sex, and state/territory, in Australia over a > 25-year period from 1994 to 2022, including during COVID-19 lockdowns. Using data from Medicare, Australia's Government-funded health insurance scheme, we retrospectively analysed corneal transplants performed from January 1994 to December 2022. From 1994 to 2022, there were 27,536 corneal transplantation services processed by Medicare. Transplants tended to be more common in males in younger age groups (67.7% male in 15-24-year-olds), and in females in older age groups (59.2% female in 75-84-year-olds). Most transplants were performed in New South Wales (9,438 services, 34.3%), Queensland (7,722, 28.0%), and Victoria (5,209, 18.9%). Annual corneal transplantation rates in Australia tended to decrease from 1994 to 2006 (lowest rate during study period), falling by 31%, and then increased by 81%, from 2006 to 2022 (end of study period). Annual repeat corneal transplantation rates (i.e. second and subsequent transplants) increased from 2004 to 2022, rising 301%. During Australia's nationwide 2020 COVID-19 lockdown (from March to April), monthly transplantation rates decreased by 31%. We performed a longitudinal analysis of corneal transplantation in Australia using a comprehensive, routinely collected, population-based data source. Prior studies examining corneal transplantation have interrogated data from the Australian Corneal Graft Registry, which relies on voluntary reporting. Corneal transplantation rates have increased during the last 15 years, likely as new corneal transplant techniques have evolved, with increasing demand for corneal donation and eye banking services.
- Open Access
- 4 October 2024
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 152, e116
Epidemiology of scarlet fever in Victoria, Australia, 2007–2017
In the last 10–15 years, there has been a global resurgence of scarlet fever, an infection historically associated with significant morbidity and mortality. It is unknown whether scarlet fever incidence has increased in Australia. We aimed to examine the incidence, predictors and severity of scarlet fever in the state of Victoria, Australia from 2007 to 2017, analyzing scarlet fever emergency department (ED) presentations, hospitalizations and deaths. Of the 1 578 scarlet fever cases during the study period, most occurred in children aged Streptococcus pyogenes variant in Australia associated with epidemic scarlet fever overseas highlights the risk of future outbreaks.
- 4 October 2024
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 152, e116
Open AccessEpidemiology of scarlet fever in Victoria, Australia, 2007–2017
In the last 10–15 years, there has been a global resurgence of scarlet fever, an infection historically associated with significant morbidity and mortality. It is unknown whether scarlet fever incidence has increased in Australia. We aimed to examine the incidence, predictors and severity of scarlet fever in the state of Victoria, Australia from 2007 to 2017, analyzing scarlet fever emergency department (ED) presentations, hospitalizations and deaths. Of the 1 578 scarlet fever cases during the study period, most occurred in children aged Streptococcus pyogenes variant in Australia associated with epidemic scarlet fever overseas highlights the risk of future outbreaks.
- 1 February 2024
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 53 (1-2) , 57-61
Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment
This retrospective population-based study examines semaglutide and dulaglutide prescriptions for type 2 diabetes supplied via the Pharmaceutical Benefits Scheme from January 2021 to September 2022.
- 1 February 2024
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 53 (1-2) , 57-61
Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment
This retrospective population-based study examines semaglutide and dulaglutide prescriptions for type 2 diabetes supplied via the Pharmaceutical Benefits Scheme from January 2021 to September 2022.
- 6 October 2023
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 52 (1) , 106-108
Increasing ocular syphilis and syphilis notifications in Australia and the state of Victoria between 2017 and 2022
- 6 October 2023
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 52 (1) , 106-108
Increasing ocular syphilis and syphilis notifications in Australia and the state of Victoria between 2017 and 2022
- Open Access
- 15 February 2023
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 31 (1) , 94-97
Intravitreal Injection Rates for Neovascular Age-Related Macular Degeneration in Australia During the 2020 COVID-19 Lockdowns
We investigate the impact of COVID-19 and lockdowns on anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD) in Victoria (Australian s...
- 15 February 2023
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 31 (1) , 94-97
Open AccessIntravitreal Injection Rates for Neovascular Age-Related Macular Degeneration in Australia During the 2020 COVID-19 Lockdowns
We investigate the impact of COVID-19 and lockdowns on anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD) in Victoria (Australian s...
- Open Access
- 10 January 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (2) , 711-726
Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019
Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level of the Australian population. National prescription data for antivirals used to treat HZ may be used as a proxy for HZ incidence. We aimed to examine trends in antiviral prescriptions supplied for the treatment of HZ in Australia pre- and post-2016, and to assess whether Zostavax’s inclusion on the NIP correlated with a reduction in HZ antiviral prescription rates. Methods Using the Australian Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescribing data, we analysed antiviral prescriptions supplied for the treatment of HZ Australia-wide between 1994 and 2019. Annual prescription rates were calculated, and trends and changes in HZ antiviral use were explored descriptively and using Poisson models. Results HZ antiviral prescription rates increased 2.6-fold (160%) between 1995 and 2015 [25.4 (95% CI 25.2, 25.6) and 65.3 (95% CI 64.9, 65.6) prescriptions per 10,000 people, respectively], and then decreased 0.45-fold (55%) between 2016 and 2018 [60.9 (95% CI 60.6, 61.2) and 27.5 (95% CI 27.3, 27.9) prescriptions per 10,000 people, respectively]. The prescription rate for the antiviral famciclovir restricted specifically for treating HZ in immunocompromised individuals increased 8.5-fold (750%) between 2006 (year first listed) and 2019 [0.3 (95% CI 0.3, 0.3) and 2.5 (95% CI 2.4, 2.6) prescriptions per 10,000 people, respectively]. Conclusion The introduction of the live-attenuated HZ vaccine on Australia’s formal national vaccination program was associated with a reduction in HZ antiviral prescription rates within the Australian population. The data suggest that the introduction of Shingrix, the non-live subunit zoster vaccine, may also be associated with a similar reduction in HZ antiviral prescriptions used to treat the immunocompromised, as well as the general population, given its accepted greater efficacy over Zostavax.
- 10 January 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (2) , 711-726
Open AccessReduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019
Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level of the Australian population. National prescription data for antivirals used to treat HZ may be used as a proxy for HZ incidence. We aimed to examine trends in antiviral prescriptions supplied for the treatment of HZ in Australia pre- and post-2016, and to assess whether Zostavax’s inclusion on the NIP correlated with a reduction in HZ antiviral prescription rates. Methods Using the Australian Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme prescribing data, we analysed antiviral prescriptions supplied for the treatment of HZ Australia-wide between 1994 and 2019. Annual prescription rates were calculated, and trends and changes in HZ antiviral use were explored descriptively and using Poisson models. Results HZ antiviral prescription rates increased 2.6-fold (160%) between 1995 and 2015 [25.4 (95% CI 25.2, 25.6) and 65.3 (95% CI 64.9, 65.6) prescriptions per 10,000 people, respectively], and then decreased 0.45-fold (55%) between 2016 and 2018 [60.9 (95% CI 60.6, 61.2) and 27.5 (95% CI 27.3, 27.9) prescriptions per 10,000 people, respectively]. The prescription rate for the antiviral famciclovir restricted specifically for treating HZ in immunocompromised individuals increased 8.5-fold (750%) between 2006 (year first listed) and 2019 [0.3 (95% CI 0.3, 0.3) and 2.5 (95% CI 2.4, 2.6) prescriptions per 10,000 people, respectively]. Conclusion The introduction of the live-attenuated HZ vaccine on Australia’s formal national vaccination program was associated with a reduction in HZ antiviral prescription rates within the Australian population. The data suggest that the introduction of Shingrix, the non-live subunit zoster vaccine, may also be associated with a similar reduction in HZ antiviral prescriptions used to treat the immunocompromised, as well as the general population, given its accepted greater efficacy over Zostavax.
- 1 June 2021
- Published by Wolters Kluwer Health in Psychiatric Genetics
- Vol. 31 (3) , 100-101
Pathophysiology and management of neuropsychiatric symptoms in succinic semialdehyde dehydrogenase deficiency
- 1 June 2021
- Published by Wolters Kluwer Health in Psychiatric Genetics
- Vol. 31 (3) , 100-101
Pathophysiology and management of neuropsychiatric symptoms in succinic semialdehyde dehydrogenase deficiency